PATENT CLAIM ANALYSIS

Application Number: 16179364
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Claim (Index 46):
The method of  claim 45 , wherein the at least one transmembrane domain comprises a transmembrane domain of a protein comprising the alpha, beta or zeta chain of the T-cell receptor, CD8, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 98.0
- Lexical Diversity: 1.55
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16161542', '15866222', '16132064', '15934770', '16050754']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7921197948562209
- 35 USC 102 Novelty (BERT): 0.6354985830756859
- Combined Prediction Score: 0.7764576736781673
- Mean Citation Score: 575.8480179999998
- Max Citation Score: 640.0974
- Similarity Product: 539.5174438278436

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test